Abbott Receives FDA Approval for CREON Infant-Specific Dosage for Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Abbott ABT announced today that the U.S. Food and Drug Administration has approved an infant-specific dose of CREON Delayed-Release Capsules to treat exocrine pancreatic insufficiency due to cystic fibrosis. The CREON 3,000 units of lipase capsule provides the lowest dosage strength in the class approved by the FDA. This new option will enable more precise dosing titration in accordance with the Cystic Fibrosis Foundation guidelines for infant dosing.